Gilead Sciences (GILD) Projected to Announce Quarterly Earnings on Monday

Gilead Sciences (NASDAQ:GILD) will likely be issuing its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect Gilead Sciences to post earnings of ($7.2479) per share and revenue of $7.4001 billion for the quarter. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Individuals can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter last year, the firm earned $1.81 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, analysts expect Gilead Sciences to post $-1 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Gilead Sciences Stock Up 2.3%

NASDAQ GILD traded up $3.05 on Tuesday, reaching $133.57. The stock had a trading volume of 2,655,524 shares, compared to its average volume of 7,097,293. The business has a 50 day moving average price of $129.56 and a 200 day moving average price of $135.68. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences has a 1 year low of $108.46 and a 1 year high of $157.29. The company has a market capitalization of $165.84 billion, a price-to-earnings ratio of 18.19 and a beta of 0.32.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer owned 607,133 shares in the company, valued at $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,000 shares of company stock worth $8,687,140 over the last ninety days. Company insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GILD. Vermillion & White Wealth Management Group LLC boosted its position in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the period. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter worth $26,000. Swiss RE Ltd. bought a new position in Gilead Sciences during the fourth quarter worth $31,000. Mcguire Capital Advisors Inc. bought a new position in Gilead Sciences during the fourth quarter worth $43,000. Finally, Palisade Asset Management LLC acquired a new position in Gilead Sciences during the 3rd quarter valued at $46,000. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on GILD shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research note on Monday, July 6th. Truist Financial cut their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Rothschild & Co Redburn cut their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, Morgan Stanley decreased their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a research report on Monday. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $158.30.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.